ZURICH (Reuters) – Pharmaceutical group Roche
“The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion,” the Swiss drug maker said in a statement. “The Roche nanopore sequencer, once developed, will utilise a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing.”
Financial details of the agreement were not disclosed.
(Reporting by Brenna Hughes Neghaiwi; editing by Thomas Seythal)